Drug Trial Radar · NCT07914894
A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 26, 2027
Primary completion
May 17, 2028
Study completion Aug 10, 2028
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an single arm, open label designed phase III study to evaluate the efficacy and safety of oral FXS6837 capsules in PNH patients with residual anemia despite the stable treatment with anti-C5 antibody.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
FXS6837 CapsuleDrug
FXS6837 capsule will be taken orally for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with hemoglobin (Hb) level ≥ 120 g/L in at least 3 of 4 measurements between Week18 and Week24 in the absence of RBC transfusion (defined as no RBC transfusion after Week2 through Week24)Time frame: 24 weeks from Baseline (Week 18 through Week 24)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TianJin Medical University General Hospital
Tianjin, China
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.